Polar Capital Holdings’s Denali Therapeutics DNLI Stock Holding History

Polar Capital Holdings’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-452,669	Closed	-$9.29M	–	284
2024 Q1	$9.29M	Hold	452,669	–	–	0.05%	205
2023 Q4	$9.71M	Sell	452,669 -554,417	-55%	-$11M	0.06%	202
2023 Q3	$20.8M	Hold	1,007,086	–	–	0.15%	139
2023 Q2	$29.7M	Buy	1,007,086 +502,086	+99%	+$14.1M	0.15%	122
2023 Q1	$11.6M	Buy	+505,000	New	+$13.9M	0.08%	179
2022 Q1	–	Sell	-53,835	Closed	-$2.4M	–	469
2021 Q4	$2.4M	Hold	53,835	–	–	0.01%	291
2021 Q3	$2.72M	Buy	53,835 +5,037	+10%	+$284K	0.01%	296
2021 Q2	$3.83M	Buy	+48,798	New	+$3.02M	0.02%	292

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Polar Capital Holdings's DNLI Position: Q2 2024 in Review

Polar Capital Holdings sold out of Denali Therapeutics (DNLI) in Q2 2024, closing a stake of 452,669 shares — an estimated $9.29M sold.

Polar Capital Holdings first reported a position in DNLI in Q2 2021 and held it in 8 quarters. The position peaked at $29.7M in Q2 2023. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2024.

Polar Capital Holdings reported no remaining Denali Therapeutics position as of Q2 2024 after selling out during the quarter.
Polar Capital Holdings sold 452,669 Denali Therapeutics shares in Q2 2024, an estimated $9.29M.
Polar Capital Holdings first reported a position in Denali Therapeutics in Q2 2021 and held it in 8 quarters.
Polar Capital Holdings's Denali Therapeutics position peaked at $29.7M in Q2 2023.
203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2024.

Based on Polar Capital Holdings's 13F filing for Q2 2024, filed 14 Aug 2024.